Finance

Lists
Why is MCRB down 5.60%?
Dive Deeper
MCRB:NASDAQ
Seres Therapeutics Inc
$2.53
-5.60%
(-0.15) 1D
Oct 13, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCRB...
Open
$2.66
High
$2.66
Low
$2.51
Mkt. cap
25.15M
Avg. vol.
71.56K
Volume
44.02K
52-wk high
$29.98
52-wk low
$2.42
EPS
-$2.33
Beta
0.31
Shares outstanding
9.94M
No. of employees
66
Open
$2.66
High
$2.66
Low
$2.51
Mkt. cap
25.15M
Avg. vol.
71.56K
Volume
44.02K
52-wk high
$29.98
52-wk low
$2.42
EPS
-$2.33
Beta
0.31
Shares outstanding
9.94M
No. of employees
66
News stories
From web sources and news partners
About Seres Therapeutics Inc
CEOEric Shaff
Employees66
Founded2010
Headquarters-
SectorBiotechnology
Websiteserestherapeutics.com
Analyst ratings
Based on 2 analysts giving stock ratings to MCRB in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MCRB in the last 3 months.
Highest
Current $2.53
$22.00 (+769.57%)
Average
$17.00 (+571.94%)
Lowest
$12.00 (+374.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$22.00
+769.6%
08/06/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
$12.00
+374.3%
08/05/2026
Edward Tenthoff
Piper Sandler
Hold
Maintained
$20.00
+690.5%
02/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
11/05/2025
Last report
Aug 5, 2026
Fiscal period
Q2 2026
$1.07 / -$2.18
+148.77%beat
Revenue / Est. (USD)
736.00K / 358.00K
+105.59%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
351.00K
438.00K
358.00K
736.00K
Cost of goods sold
13.35M
12.28M
13.20M
9.14M
Cost of revenue
13.35M
12.28M
13.20M
9.14M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.48M
7.54M
8.07M
7.06M
Operating expense
9.48M
7.54M
8.07M
7.06M
Total operating expenses
22.83M
19.82M
21.26M
16.20M
Operating income
-22.48M
-19.38M
-20.91M
-15.47M
Other non operating income
2.84M
2.33M
669.00K
673.00K
EBT including unusual items
8.20M
-15.34M
-19.91M
4.58M
EBT excluding unusual items
-19.02M
-16.60M
-19.91M
-14.61M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
8.20M
-15.34M
-19.91M
4.58M
Net profit margin
2,337.32%
-3,501.14%
-5,562.29%
622.42%
Earnings per share
0.94
-1.76
-2.08
1.07
Interest and investment income
618.00K
445.00K
325.00K
181.00K
Interest expense
-
-
-
-
Net interest expenses
618.00K
445.00K
325.00K
181.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.43M
-18.42M
-20.13M
-14.80M
Gain or loss from assets sale
-
-192.00K
-
139.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps